The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022

Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022

November 28, 2022 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus.

You Might Also Like
  • Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session
  • Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE
  • ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings
Also By This Author
  • Study Explores Palindromic Rheumatism to Predict RA Development

Remibrutinib in Phase 2 Sjögren’s Syndrome Trial

Thomas Dörner, MD

Thomas Dörner, MD

Thomas Dörner, MD, a professor of rheumatology and clinical immunology for innovative therapies at Charite University Hospital Berlin and DRFZ Berlin, presented promising but mixed phase 2 results of remibrutinib, an oral inhibitor of Bruton’s tyrosine kinase (BTK), in Sjögren’s syndrome.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Dörner explained that even though the predominant cells infiltrating the exocrine glands in Sjögren’s syndrome are CD4-positive T cells, the syndrome is considered a B cell driven autoimmune disease resulting from abnormal response to autoantigens. Currently, no systemic oral therapies for the treatment of Sjögren’s syndrome have been approved by the U.S. Food & Drug Administration (FDA) to reduce the mouth and eye dryness, fatigue and joint pain associated with the condition, and the disease is often difficult to adequately treat.2

BTK plays a critical role in B cell receptor signaling, influencing B cell proliferation and differentiation. It also affects proinflammatory signaling through immunoglobulin Fc receptors, such as those in mast cells and macrophages. Various BTK kinase inhibitors are used to treat B cell malignancies, but agents currently approved for malignancy have significant off-target effects on other kinases. These cause side effects that have limited their use in other disease settings; these adverse side effects include platelet activation, which can cause stroke, and other cardiovascular effects.3,4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Remibrutinib (LOU064) is a novel BTK inhibitor with different binding characteristics and greater selectivity for BTK than previously developed drugs.3 Scientists have been exploring the drug in various autoimmune, allergic and inflammatory diseases, such as multiple sclerosis and chronic spontaneous urticaria, which recently completed a successful phase 2 trial.5,6

LOUiSSe Trial Results

The LOUiSSe trial was a double-blind, randomized, placebo-controlled phase 2 trial to evaluate efficacy and safety in patients with moderate to severe Sjögren’s syndrome.1 All patients met ACR classification criteria for Sjögren’s syndrome and had a score of 5 or higher on the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), a clinician-reported outcome that includes 12 different domains of disease activity.1,7

All participants also had an initial score of 5 or higher on the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI). On this questionnaire, patients scale their dryness, fatigue and joint/muscle pain from 0–10 over the previous two weeks, and the mean of the three domains is the ESSPRI score.7

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, SLE (Lupus) Tagged With: ACR Convergence 2022, Dörner, Lupus, Pike, Sjögren's syndrome, SLE, SLE Resource Center, systemic lupus erythematous

You Might Also Like:
  • Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session
  • Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE
  • ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings
  • Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)